Scientific, Regulatory & Legal Dimensions of Recent Advances in Gene Editing

Join us at an exciting CeBIL/CORS seminar on 4 March 2019 featuring gene-editing pioneer Feng Zhang from the Broad Institute, as well as legal and regulatory experts.

Timo Minssen and Feng Zhang

Timo Minssen and Feng Zhang 

Gene editing technologies, such as CRISPR-Cas 9 and Cas 13, enable scientists to add, remove, or alter genetic material at particular locations in the genome. In addition to their enormous potential for many useful applications in the plant sciences, gene-editing technologies are also of great interest in the prevention and treatment of human maladies. It holds e.g. great promise for the development of therapies against various diseases, such as single-gene disorders including sickle cell disease, hemophilia, and cystic fibrosis. Gene editing is also being explored for the treatment and prevention of more complex diseases, such as mental illness, HIV infections, cancer and cardio-vascular disorders.

Yet, recent developments have also demonstrated that severe concerns arise when genome editing is used to alter human genomes. Germline cell and embryo genome editing bring up a number of ethical and regulatory challenges, including whether it would be permissible to use this technology to enhance normal human traits.

This interdisciplinary seminar will debate the most recent advances in gene editing and the resulting legal and regulatory challenges. It features leading experts in the field, including Professor Feng Zhang from the Broad Institute, who is one of the world’s leading gene editing pioneers.

Speakers abstract titles

Speakers abstract titles (pdf)

Agenda & timing




9.00 - 09.15

Timo Minssen

Welcome & Introduction

9.15 – 09.45

Feng Zhang

Harnessing Microbial Diversity for Gene Editing and Beyond

09.45 – 10.15

Marie Louise (Marieke) De Bruin

Authorisation of Gene- and Cell-Based Therapies and Regulatory Decision-Making

10.15 – 10.30

Break: Mingel & Snacks


10.30 – 11.00

Esther Van Zimmeren & Timo Minssen

Ethical Licensing for CRISPR: Exploring the Opportunities for Responsible Licensing Mechanisms to Restore Trust

11.00 – 11.45

Panel debate with speakers
& Sven Bostyn

Moderator: Janne Rothmar Herrmann

The Quest for Balance: Addressing and Regulating the Risk and Opportunities of Recent Advances in Gene Editing

 11.45 – 12.30

Light lunch & Mingle


Time:  4 March 2019, 9:00 - 13:00

Place:  Nielsine Nielsen Auditorium in Maersk Tower, 3b Blegdamsvej, DK-2200 Copenhagen N, Denmark


Please register using this registration form.


Timo Minssen, Center for Advanced Studies in Biomedical Innovation Law (CeBIL) and Copenhagen Center for Regulatory Sciences (CORS)